Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy
- 1 September 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 4 (9), 1014-1021
- https://doi.org/10.1158/2159-8290.cd-14-0380
Abstract
Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functional analysis of an outlier curative response of a patient with metastatic small-cell cancer to combined checkpoint kinase 1 (CHK1) inhibition and DNA-damaging chemotherapy. Whole-genome sequencing revealed a clonal hemizygous mutation in the Mre11 complex gene RAD50 that attenuated ATM signaling which in the context of CHK1 inhibition contributed, via synthetic lethality, to extreme sensitivity to irinotecan. As Mre11 mutations occur in a diversity of human tumors, the results suggest a tumor-specific combination therapy strategy in which checkpoint inhibition in combination with DNA-damaging chemotherapy is synthetically lethal in tumor cells but not normal cells with somatic mutations that impair Mre11 complex function. Significance: Strategies to effect deep and lasting responses to cancer therapy in patients with metastatic disease have remained difficult to attain, especially in early-phase clinical trials. Here, we present an in-depth genomic and functional genetic analysis identifying RAD50 hypomorphism as a contributing factor to a curative response to systemic combination therapy in a patient with recurrent, metastatic small-cell cancer. Cancer Discov; 4(9); 1014–21. ©2014 AACR. See related commentary by Peng et al., p. 988 This article is highlighted in the In This Issue feature, p. 973Other Versions
This publication has 18 references indexed in Scilit:
- Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder CancerJournal of Clinical Oncology, 2013
- Genome Sequencing Identifies a Basis for Everolimus SensitivityScience, 2012
- Mre11–Rad50 complex crystals suggest molecular calisthenicsDNA Repair, 2011
- An Interaction between the Walker A and D-loop Motifs Is Critical to ATP Hydrolysis and Cooperativity in Bacteriophage T4 Rad50Online Journal of Public Health Informatics, 2011
- Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.Journal of Clinical Oncology, 2011
- The MRE11 complex: starting from the endsNature Reviews Molecular Cell Biology, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- ATP Binding to the Motor Domain from an ABC Transporter Drives Formation of a Nucleotide Sandwich DimerMolecular Cell, 2002
- A DNA Damage Response Pathway Controlled by Tel1 and the Mre11 ComplexMolecular Cell, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2000